{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:51:23Z","timestamp":1787021483628,"version":"build-2736575974"},"reference-count":39,"publisher":"Medical Association of Nippon Medical School","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2012]]},"DOI":"10.1272\/jnms.79.204","type":"journal-article","created":{"date-parts":[[2012,7,5]],"date-time":"2012-07-05T23:13:34Z","timestamp":1341530014000},"page":"204-212","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Gemcitabine Monotherapy for Patients with Advanced Biliary Tract Cancer"],"prefix":"10.1272","volume":"79","author":[{"given":"Tadashi","family":"Yokoyama","sequence":"first","affiliation":[{"name":"Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Surgery, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Surgery, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Makino","sequence":"additional","affiliation":[{"name":"Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Surgery, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Surgery, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Surgery, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Matsutani","sequence":"additional","affiliation":[{"name":"Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Surgery, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Surgery, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hirakata","sequence":"additional","affiliation":[{"name":"Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Surgery, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasajima","sequence":"additional","affiliation":[{"name":"Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Surgery, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Verslype C, Prenen H, Van Cutsem E: The role of chemotherapy in biliary tract carcinoma. HPB (Oxford) 2008; 10: 164-167.","DOI":"10.1080\/13651820802029427"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Raderer M, Hejna MH, Valencak JB, et al.: Two consecutive phase II studies of 5-fluorouracil\/leucovorin\/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999; 56: 177-180.","DOI":"10.1159\/000011961"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Davis HL Jr, Ramirez G, Ansfield FJ: Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy. Cancer 1974; 33: 193-197.","DOI":"10.1002\/1097-0142(197401)33:1<193::AID-CNCR2820330128>3.0.CO;2-S"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Falkson G, MacIntyre JM, Moertel CG: Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54: 965-969.","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Taal BG, Audisio RA, Bleiberg H, et al.: Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol 1993; 4: 607-609.","DOI":"10.1093\/oxfordjournals.annonc.a058597"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Okada S, Ishii H, Nose H, et al.: A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 1994; 51: 515-517.","DOI":"10.1159\/000227396"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T: Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51: 396-400.","DOI":"10.1159\/000227373"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ: Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996; 14: 2306-2310.","DOI":"10.1200\/JCO.1996.14.8.2306"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Pazdur R, Royce ME, Rodriguez GI, et al.: Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol 1999; 22: 78-81.","DOI":"10.1097\/00000421-199902000-00019"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Papakostas P, Kouroussis C, Androulakis N, et al.: First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 2001; 37: 1833-1838.","DOI":"10.1016\/S0959-8049(01)00214-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Okusaka T: Chemotherapy for biliary tract cancer in Japan. Semin Oncol 2002; 29: 51-53.","DOI":"10.1053\/sonc.2002.37377"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Furuse J, Okusaka T, Ohkawa S, et al.: A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol 2009; 65: 113-120.","DOI":"10.1007\/s00280-009-1011-z"},{"key":"13","unstructured":"13. Hertel LW, Boder GB, Kroin JS, et al.: Evaluation of the antitumor activity of gemcitabine. Caricer Res 1990; 50: 4417-4422."},{"key":"14","unstructured":"14. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-6117."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Burris HA 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.","DOI":"10.1200\/JCO.1997.15.6.2403"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ohkawa S: Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol2004; 22: 14S. Abstract 4131.","DOI":"10.1200\/jco.2004.22.90140.4131"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Louvet C, Labianca R, Hammel P, et al.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516.","DOI":"10.1200\/JCO.2005.06.023"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Reni M, Cordio S, Milandri C, et al.: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6: 369-376.","DOI":"10.1016\/S1470-2045(05)70175-3"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hermann R, Bodoky G, Ruhstaller T, et al.: Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative OncologyGroup (CECOG). Proc Am Soc Clin Oncol 2005; 23: 310s. Abstract LBA4010.","DOI":"10.1200\/jco.2005.23.16_suppl.lba4010"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Heinemann V, Quietzsch D, Gieseler F, et al.: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952.","DOI":"10.1200\/JCO.2005.05.1490"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Xie de R, Liang HL, Wang Y, Guo SS: Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone. Chin J Dig Dis 2006; 7: 49-54.","DOI":"10.1111\/j.1443-9573.2006.00244.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Raderer M, Hejna MH, Valencak JB, et al.: Two consecutive phase II studies of 5-FU\/leucovorin\/mitomycin and of gemcitabine in patients with advanced biliary cancer. Oncology 1999; 56: 177-180.","DOI":"10.1159\/000011961"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Penz M, Kornek GV, Raderer M, et al.: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12: 183-186.","DOI":"10.1023\/A:1008352123009"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Gebbia V, Giuliani F, Maiello E, et al.: Treatment of inoperable and\/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001; 19: 4089-4091.","DOI":"10.1200\/JCO.2001.19.20.4089"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Gallardo JO, Rubio B, Fodor M, et al.: A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001; 12: 1403-1406.","DOI":"10.1023\/A:1012543223020"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lin MH, Chen JS, Chen HH, Su WC: A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 2003; 49: 154-158.","DOI":"10.1159\/000070622"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Eng C, Ramanathan RK, Wong MK, et al.: A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 2004; 27: 565-569.","DOI":"10.1097\/01.coc.0000135924.94955.16"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tsavaris N, Kosmas C, Gouveris P, et al.: Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004; 22: 193-198.","DOI":"10.1023\/B:DRUG.0000011797.09549.53"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Park JS, Oh SY, Kim SH, et al.: Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 2005; 35: 68-73.","DOI":"10.1093\/jjco\/hyi021"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid RM, Eckel F: Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 2005; 5: 61.","DOI":"10.1186\/1471-2407-5-61"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Okusaka T, Ishii H, Funakoshi A, et al.: Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006; 57: 647-653.","DOI":"10.1007\/s00280-005-0095-3"},{"key":"32","unstructured":"32. Reyes-Vidal J, Gallardo J, Yanez E, et al.: Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: results of the phase II Gocchi study 2000-13. Proc Am Soc Clin Oncol2003; 22: 273(Abstr 1095)."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Andre T, Tournigand C, Rosmorduc O, et al.: Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15: 1339-1343.","DOI":"10.1093\/annonc\/mdh351"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Doval DC, Sekhon JS, Gupta SK, et al.: A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004; 90: 1516-1520.","DOI":"10.1038\/sj.bjc.6601736"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Knox JJ, Hedley D, Oza A, et al.: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23: 2332-2338.","DOI":"10.1200\/JCO.2005.51.008"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.","DOI":"10.1093\/jnci\/92.3.205"},{"key":"37","unstructured":"37. National Cancer Institute-Common Toxicity Criteria (NCI-CTC Version 2.0, April 30, 1999)."},{"key":"38","unstructured":"38. Saisho T, Okusaka T, Ueno H, Morizane C, Okada S: Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Hepatogastroenterology 2005; 52: 1654-1658."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Park I, Lee JL, Ryu MH, et al.: Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer 2009; 115: 4148-4155.","DOI":"10.1002\/cncr.24472"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/79\/3\/79_204\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T03:43:52Z","timestamp":1616989432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/79\/3\/79_204\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.79.204","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}